191 related articles for article (PubMed ID: 12823342)
1. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.
Goulden N; Bader P; Van Der Velden V; Moppett J; Schilham M; Masden HO; Krejci O; Kreyenberg H; Lankester A; Révész T; Klingebiel T; Van Dongen J
Br J Haematol; 2003 Jul; 122(1):24-9. PubMed ID: 12823342
[TBL] [Abstract][Full Text] [Related]
2. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis.
Shen Z; Gu X; Mao W; Yin L; Yang L; Zhang Z; Liu K; Wang L; Huang Y
BMC Cancer; 2018 Jul; 18(1):755. PubMed ID: 30037340
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
[TBL] [Abstract][Full Text] [Related]
4. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
7. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation.
Sánchez J; Serrano J; Gómez P; Martínez F; Martín C; Madero L; Herrera C; García JM; Casaño J; Torres A
Br J Haematol; 2002 Mar; 116(3):686-94. PubMed ID: 11849234
[TBL] [Abstract][Full Text] [Related]
9. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia.
Uzunel M; Jaksch M; Mattsson J; Ringdén O
Br J Haematol; 2003 Sep; 122(5):788-94. PubMed ID: 12930390
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.
Bourlon C; Lacayo-Leñero D; Inclán-Alarcón SI; Demichelis-Gómez R
Curr Oncol Rep; 2018 Mar; 20(4):36. PubMed ID: 29577208
[TBL] [Abstract][Full Text] [Related]
12. Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.
Pochon C; Oger E; Michel G; Dalle JH; Salmon A; Nelken B; Bertrand Y; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rohrlich P; Paillard C; Demeocq F; Schneider P; Plantaz D; Poirée M; Eliaou JF; Semana G; Drunat S; Jonveaux P; Bordigoni P; Gandemer V
Br J Haematol; 2015 Apr; 169(2):249-61. PubMed ID: 25522886
[TBL] [Abstract][Full Text] [Related]
13. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan.
Imashuku S; Terui K; Matsuyama T; Asami K; Tsuchiya S; Ishii E; Kawa K; Kosaka Y; Eguchi H; Tsuchida M; Ikuta K; Kato S; Koizumi S; Okamura J; Morimoto A; Hibi S; Hamaoka K;
Bone Marrow Transplant; 2003 Jun; 31(12):1127-35. PubMed ID: 12796792
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia.
Knechtli CJ; Goulden NJ; Hancock JP; Harris EL; Garland RJ; Jones CG; Grandage VL; Rowbottom AW; Green AF; Clarke E; Lankester AW; Potter MN; Cornish JM; Pamphilon DH; Steward CG; Oakhill A
Br J Haematol; 1998 Aug; 102(3):860-71. PubMed ID: 9722317
[TBL] [Abstract][Full Text] [Related]
15. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
16. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review.
Oliansky DM; Camitta B; Gaynon P; Nieder ML; Parsons SK; Pulsipher MA; Dillon H; Ratko TA; Wall D; McCarthy PL; Hahn T;
Biol Blood Marrow Transplant; 2012 Apr; 18(4):505-22. PubMed ID: 22209888
[TBL] [Abstract][Full Text] [Related]
17. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL.
Goulden N; Steward C
Best Pract Res Clin Haematol; 2002 Mar; 15(1):59-70. PubMed ID: 11987916
[TBL] [Abstract][Full Text] [Related]
20. The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
Moppett J; Burke GA; Steward CG; Oakhill A; Goulden NJ
J Clin Pathol; 2003 Apr; 56(4):249-53. PubMed ID: 12663634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
